Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.48) by 16.67 percent. This is a 29.82 percent increase over losses of $(0.57) per share from the same period last year. The company reported quarterly sales of $3.165 million which missed the analyst consensus estimate of $4.728 million by 33.06 percent. This is a 39.13 percent decrease over sales of $5.200 million the same period last year.